Key result
Ethinylestradiol and cyproterone acetate improves FMD by ~5% from baseline in young women with PCOS.
Why the study?
Combined oral contraceptives are used in PCOS women for hyperandrogenism and menstrual disturbances, but their effect on endothelial function in young, non-obese PCOS women is unclear.
Does ethinylestradiol/cyproterone acetate improve endothelial function in young non-obese women with polycystic ovary syndrome?
Does ethinylestradiol/cyproterone acetate improve endothelial function in young non-obese women with polycystic ovary syndrome?
Answers are grounded in this paper and cite their sources.
Treatment with ethinylestradiol and cyproterone acetate reverses endothelial dysfunction in young, non-obese women with PCOS, likely by reducing hyperandrogenism.
BACKGROUND: Combined oral contraceptives are used in polycystic ovary syndrome (PCOS) women for the treatment of hyperandrogenism and menstrual cycle disturbances. AIM: To assess the effect of ethinylestradiol and cyproterone acetate (EE/CA) on endothelial function in young, non-obese PCOS women in a pilot study. METHODS: Thirteen young, non-obese PCOS women (20.9 ± 3.7 years, 23.0 ± 4.0 kg/m(2)) received 35 mcg EE & 2 mg CA for 6 months. Fourteen age- and body mass index (BMI)-matched healthy women served as controls. Endothelial function assessed by brachial artery flow-mediated dilation (FMD), indices of hyperandrogenism, and insulin resistance were studied at baseline and 6-month follow-up. RESULTS: FMD was impaired in PCOS compared to control women (4.67 ± 2.38% vs. 10.12 ± 3.19%, p < 0.001), but increased significantly following EE/CA (9.99 ± 2.11%, p < 0.001 vs. baseline), reaching normal values (p = NS vs. controls). EE/CA also significantly decreased hyperandrogenism indices and increased total and HDL cholesterol and triglycerides (p < 0.05 vs. baseline). The only independent predictor of treatment-induced FMD improvement in PCOS women was the decrease in free androgen index. CONCLUSIONS: Treatment with combination of estrogens and antiandrogens reverses endothelial dysfunction in young, non-obese PCOS women mainly via improving hyperandrogenism. Further research is needed to investigate whether this treatment may also reduce cardiovascular risk in these women.
No takes yet. Share an insight, caveat, or question.
Naka et al. (2011) studied polycystic ovary syndrome (PCOS) (n=27). ethinylestradiol and cyproterone acetate vs. Baseline was evaluated on brachial artery flow-mediated dilation (FMD) (p=<0.001). Treatment with ethinylestradiol and cyproterone acetate improved flow-mediated dilation in young, non-obese women with PCOS from 4.67% at baseline to 9.99% at 6 months.
Synapse has enriched 10 related papers. Consider them for comparative context: